Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 2/20 | 0.72 |
| ▸ | MAOA | P21397 | 6/20 | 0.71 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.71 |
| ▸ | ESR1 | P03372 | 5/20 | 0.71 |
| ▸ | MAOB | P27338 | 2/20 | 0.71 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.71 |
| ▸ | MEN1 | O00255 | 5/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.61 |
| ▸ | MAPT | P10636 | 4/20 | 0.61 |
| ▸ | HPGD | P15428 | 4/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.55 |
| ▸ | RECQL | P46063 | 3/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.55 |
| ▸ | APEX1 | P27695 | 2/20 | 0.55 |
| ▸ | BRCA1 | P38398 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Anthraflavicacid SCHEMBL28102629 | 0.92 | MAOA (0.70) | TTRMAOAESR2ESR1MAOB | |
| SCHEMBL30695849 | 0.84 | TTR (1.00) | TTRMAOAESR2ESR1MAOB | |
| SCHEMBL1507679 | 0.84 | TTR (1.00) | TTRMAOAESR2ESR1MAOB | |
| SCHEMBL6904810 | 0.84 | MAOA (0.70) | TTRMAOAESR2ESR1MAOB | |
| SCHEMBL30695846 | 0.84 | TTR (1.00) | TTRMAOAESR2ESR1MAOB | |
| SCHEMBL1495097 | 0.84 | TTR (1.00) | TTRMAOAESR2ESR1MAOB | |
| Anthraflavicacid SCHEMBL29985684 | 0.84 | ESR2 (1.00) | TTRMAOAESR2ESR1MAOB | |
| Anthraflavicacid SCHEMBL31105422 | 0.84 | ESR2 (1.00) | TTRMAOAESR2ESR1MAOB | |
| SCHEMBL2772476 | 0.84 | ESR2 (1.00) | TTRMAOAESR2ESR1MAOB | |
| Anthraflavicacid SCHEMBL124974 | 0.84 | ESR2 (1.00) | TTRMAOAESR2ESR1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3280402-B1 | TOLAN COMPOUNDS FOR PROMOTING WOUND HEALING | BIOMENDICS LLC (US) | 2024-06-05 | — | — | EP | claimed |
| EP-3280402-B1 | TOLAN COMPOUNDS FOR PROMOTING WOUND HEALING | BIOMENDICS LLC (US) | 2024-06-05 | — | — | EP | disclosed |
| CN-107847466-B | Formulations and methods for modulating wound healing | 贝欧曼蒂克丝公司 | 2024-02-06 | — | — | CN | disclosed |
| US-11786481-B2 | Formulation and process for modulating wound healing | BioMendics, LLC (US) | 2023-10-17 | — | — | US | disclosed |
| US-11421223-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| US-20210228501-A1 | Formulation and Process for Modulating Wound Healing | BioMendics, LLC (US) | 2021-07-29 | — | — | US | disclosed |
| US-20190309289-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. | 2019-10-10 | — | — | US | disclosed |
| US-10426742-B2 | Formulation and process for modulating wound healing | BioMendics, LLC (US) | 2019-10-01 | — | — | US | disclosed |
| US-10370654-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20190022029-A1 | Formulation and Process for Modulating Wound Healing | BioMendics, LLC (US) | 2019-01-24 | — | — | US | disclosed |
| US-20160296477-A1 | Formulation and Process for Modulating Wound Healing | BioMendics, LLC (US) | 2016-10-13 | — | — | US | disclosed |
| WO-2016164531-A2 | FORMULATION AND PROCESS FOR MODULATING WOUND HEALING | BioMendics, LLC (US) | 2016-10-13 | — | — | WO | disclosed |
| US-20160186168-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. | 2016-06-30 | — | — | US | disclosed |
| US-6815481-B2 | FUSED DIBENZO THERMAL STABILIZERS SUCH AS ANTHRACENE, XANTHENE AND ANTHRONE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-11-09 | — | — | US | disclosed |
| US-20020032256-A1 | Polybutadiene composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-03-14 | — | — | US | disclosed |
| EP-0320227-B1 | Method of preventing polymer-scale formation | SHINETSU CHEMICAL CO (JP) | 1994-09-07 | — | — | EP | disclosed |
| US-4933399-A | COATING INSIDE OF VESSEL WITH A CATIONIC DYE, DRYING, COATING WITH AN ANIONIC OR AMPHOTERIC POLYMER OR A HYDROXYL-CONTAINING COMPOUND IN A SOLVENT | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1990-06-12 | — | — | US | disclosed |
| EP-0137262-B1 | MONO- AND BIFUNCTIONAL ANTHRAQUINONE-(OXY-2,3-OXIDOPROPANES), METHOD FOR THEIR PREPARATION AND THEIR USE AS MEDICINES | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-02-15 | — | — | EP | disclosed |
| US-4762648-A | ADRENERGIC BLOCKING AGENTS, CROSSLINKING AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-08-09 | — | — | US | disclosed |
| EP-0137262-A1 | Mono- and bifunctional anthraquinone-(oxy-2,3-oxidopropanes), method for their preparation and their use as medicines | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-04-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11786481-B2 | Formulation and process for modulating wound healing | SQSTM1, ATG7, TFEB | TTR 2797/4885MAOA 4700/4885ESR2 4058/4885 |
| US-20160296477-A1 | Formulation and Process for Modulating Wound Healing | SQSTM1, ATG7, TFEB | TTR 2988/4885MAOA 4676/4885ESR2 4022/4885 |
| US-20210228501-A1 | Formulation and Process for Modulating Wound Healing | ATG7, SQSTM1, ATF4 | TTR 2045/4885MAOA 4389/4885ESR2 4242/4885 |
| US-10426742-B2 | Formulation and process for modulating wound healing | SQSTM1, ATG7, TFEB | TTR 2797/4885MAOA 4700/4885ESR2 4058/4885 |
| US-20190022029-A1 | Formulation and Process for Modulating Wound Healing | SQSTM1, ATG7, TFEB | TTR 2797/4885MAOA 4700/4885ESR2 4058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.